news-med.jpg

Aptuit Announces Alignment of Organizational Structure to Integrated Solution Delivery: Henning Steinhagen Appointed as President, Research and Development Operations

Greenwich, CT, April 6, 2017 – Jonathan Goldman, CEO of Aptuit LLC, announced today that Henning Steinhagen, PhD, has been named as President, Research and Development Operations. Henning will continue in his existing role of Site-Head at Aptuit, Verona, Italy whilst assuming oversight of Aptuit ...

Topics: Corporate, Partner Research Organization Read More

SAMDI Tech, Inc. and Aptuit Announce Drug Discovery Screening Partnership

CHICAGO, IL – February 7, 2017 – SAMDI Tech, Inc. and Aptuit, LLC are partnering to broaden their portfolio of assay development and high-throughput drug discovery services in Europe and North America. The partnership provides early-stage drug discovery researchers with access to SAMDI Tech’s ...

Topics: Strategy, Corporate, Business, Drug design and discovery Read More

Aptuit announces drug discovery collaboration with Massachusetts General Hospital (MGH) to identify novel treatments for Gram-negative infections

Greenwich, CT - January 24, 2017 - Aptuit, LLC today announced the start of a collaboration with the Molecular Surgical Laboratory of Massachusetts General Hospital (MGH), directed by Dr. Laurence Rahme, aimed at the identification and validation of novel targets in Gram-negative bacteria. Aptuit ...

Topics: Corporate, Drug design and discovery Read More

Chronos Therapeutics partners with Aptuit for addictive behaviour programmes

Oxford, UK - January 9, 2017 - Chronos Therapeutics Ltd (Chronos), the private biotech company focused on ageing diseases, brain and nervous system disorders, announced that they have partnered with a subsidiary of Aptuit Holdings LLC (Aptuit) for services related to Chronos’ programme targeting ...

Topics: Corporate, Business Read More

Aptuit and Chiesi Initiate Integrated Discovery Project to Identify Novel Compounds for the Treatment of Idiopathic Pulmonary Fibrosis

Greenwich, CT, and Parma, Italy – January 4, 2017 Aptuit, LLC, a premier global drug discovery and development CRO, and Chiesi Farmaceutici (Chiesi), an international research-focused Healthcare Group, announced today that they have entered an agreement under which Aptuit will conduct an integrated ...

Topics: Corporate, Business, Drug design and discovery Read More

Aptuit Announces Expansion of Compound Library

Part of 5m$ Investment in Integrated Drug Discovery Capabilities Greenwich, CT, November 30, 2016 - Aptuit, LLC today announced that it had successfully completed the expansion of their lead-like screening library. An additional 150,000 novel compounds have increased the Screening Collection to ...

Topics: Corporate, Business Read More

Aptuit names Peter Gray as the new Chairman of Aptuit Holdings, LLC

Greenwich, CT, November 28, 2016 – Aptuit today announced that Peter Gray has been appointed Chairman of Aptuit’s Board of Managers. Mr. Gray assumes the role of Chairman having previously served as Non-Executive Director since March 2015. Mr. Gray said, “I am honoured to assume the role of ...

Topics: Corporate Read More

Aptuit LLC and Dimension Therapeutics enter strategic partnership to advance select Dimension programs toward IND filing

Aptuit Greenwich, CT, and Cambridge, MA - July 7, 2016 – Aptuit LLC, a premier global drug discovery and development CRO, and Dimension Therapeutics, a biopharmaceutical company advancing novel, adeno-associated virus (AAV) gene therapies targeting the liver, a key organ for human metabolism, ...

Topics: Strategy, Corporate, Business Read More

Aptuit CEO, Jonathan Goldman, joins the Columbia University Healthcare Advisory Board

Greenwich, CT, November 30, 2015 - We are very pleased to announce that Jonathan Goldman, CEO of Aptuit, has accepted a nomination to join the Columbia University Healthcare Advisory Board. Jonathan will serve an initial three-year term on the board alongside other executives from leading ...

Topics: Corporate, Business Read More